Preventing CMV infection after lung transplant
Treatments studied
Part of Infections clinical trials.
This study tests a new drug called letermovir, given after a lung transplant, to see if it prevents CMV infection better than the current standard drug, valganciclovir. If you're at high risk for CMV, this trial could help protect you from this common post-transplant infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have received a lung transplant and be at high risk for CMV (donor was CMV-positive, you were CMV-negative before transplant).
- Your CMV test must show no active virus before starting the study drug.
- You cannot be HIV-positive or have received a multi-organ transplant.
- You must be able to follow the study schedule and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This study tests a drug called letermovir to see if it can help prevent a common virus called CMV from causing problems after your transplant. It's for people who have had a kidney or liver transplant and carry the virus.
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Hear when a new Infections, Cytomegalovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.